Podocytes as a target of prorenin in diabetes

Current Diabetes Reviews

Volumn 7, Issue 1, 2011, Pages 17-21

  Sakoda, Mariyo ^a,b   Itoh, Hiroshi ^a   Ichihara, Atsuhiro ^a,c  

^a University School of Medicine ^*  (Japan)

^b Japan Society for the Promotion of Science   (Japan)

^c Institute for Advanced Medical Research   (Japan)

Author keywords

(Pro)renin receptor; Albuminuria; Glomerular filtration barrier; Proteinuria; Stretching

Indexed keywords

ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSINOGEN; GLUCOSE; MESSENGER RNA; PRORENIN; PRORENIN RECEPTOR; PRORENIN RECEPTOR BLOCKING AGENT; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ALBUMINURIA; APOPTOSIS; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DRUG TARGETING; EXPERIMENTAL STUDY; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; MESANGIUM CELL; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN TARGETING; PROTEINURIA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SIGNAL TRANSDUCTION; STREPTOZOCIN DIABETES; TRANSGENIC RAT; UPREGULATION;

EID: 79952753333     PISSN: 15733998     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339911794273955     Document Type: Review

References (48)

1. Mogensen CE, Christensen CK. Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med 1984; 311(2): 89-93.
2. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984; 310(6): 356-360.
3. Jensen T, Bjerre-Knudsen J, Feldt-Rasmussen B, Deckert T. Fea-tures of endothelial dysfunction in early diabetic nephropathy. Lancet 1989; 1(8636): 461-463.
4. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Ko-foed-Enevoldsen A. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia 1989; 32(4): 219-226.
5. Kefalides NA. Basement membrane research in diabetes mellitus. Coll Relat Res 1981; 1(3): 295-299.
6. Comper WD, Russo LM. The glomerular filter: an imperfect bar- rier is required for perfect renal function. Curr Opin Nephrol Hy-pertens 2009; 18(4): 336-342.
7. Levick JR, Smaje LH. An analysis of the permeability of a fenestra. Microvasc Res 1987; 33(2): 233-256.
8. Singh A, Satchell SC, Neal CR, McKenzie EA, Tooke JE, Mathi-eson PW. Glomerular endothelial glycocalyx constitutes a barrier to protein permeability. J Am Soc Nephrol 2007; 18(11): 2885-2893.
9. Lennon R, Singh A, Welsh GI, et al. Hemopexin induces nephrin- dependent reorganization of the actin cytoskeleton in podocytes. J Am Soc Nephrol 2008; 19(11): 2140-2149.
10. Deen WM, Lazzara MJ, Myers BD. Structural determinants of glomerular permeability. Am J Physiol Renal Physiol 2001; 281(4): F579-596.
11. Deen WM. What determines glomerular capillary permeability? J Clin Invest 2004; 114(10): 1412-1414.
12. Vernier RL, Steffes MW, Sisson-Ross S, Mauer SM. Heparan sulfate proteoglycan in the glomerular basement membrane in type 1 diabetes mellitus. Kidney Int 1992; 41(4): 1070-1080.
13. Menne J, Park JK, Boehne M, et al. Diminished loss of proteogly-cans and lack of albuminuria in protein kinase C-alpha-deficient diabetic mice. Diabetes 2004; 53(8): 2101-2109.
14. Ijpelaar DH, Schulz A, Koop K, et al. Glomerular hypertrophy precedes albuminuria and segmental loss of podoplanin in podo-cytes in Munich-Wistar-Fromter rats. Am J Physiol Renal Physiol 2008; 294(4): F758-767.
15. Steffes MW, Leffert JD, Basgen JM, Brown DM, Mauer SM. Epi-thelia cell foot process width in intact and uninephrectomized diabetic and nondiabetic rats. Lab Invest 1980; 43(3): 225-230.
16. Pagtalunan ME, Miller PL, Jumping-Eagle S, et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997; 99(2): 342-348.
17. Yu D, Petermann A, Kunter U, Rong S, Shankland SJ, Floege J. Urinary podocyte loss is a more specific marker of ongoing glome-rular damage than proteinuria. J Am Soc Nephrol 2005; 16(6): 1733-1741.
18. Satchell SC, Tooke JE. What is the mechanism of microalbuminu-ria in diabetes: a role for the glomerular endothelium? Diabetologia 2008; 51(5): 714-725.
19. Dalla Vestra M, Masiero A, Roiter AM, Saller A, Crepaldi G, Fioretto P: Is podocyte injury relevant in diabetic nephropathy? Studies in patients with type 2 diabetes. Diabetes 2003; 52(4): 1031-1035.
20. Ichihara A, Kaneshiro Y, Takemitsu T, Sakoda M, Itoh H. The (pro)renin receptor and the kidney. Semin Nephrol 2007; 27(5): 524-528.
21. Suzuki F, Hayakawa M, Nakagawa T, et al. Human prorenin has gate and handle regions for its non-proteolytic activation. J Biol Chem 2003; 278(25): 22217-22222.
22. Nabi AH, Kageshima A, Uddin MN, Nakagawa T, Park EY, Suzuki F. Binding properties of rat prorenin and renin to the recombi-nant rat renin/prorenin receptor prepared by a baculovirus expression system. Int J Mol Med 2006; 18(3): 483-488.
23. Nabi AH, Biswas KB, Nakagawa T, Ichihara A, Inagami T, Suzuki F. 'Decoy peptide' region (RIFLKRMPSI) of prorenin prosegment plays a crucial role in prorenin binding to the (pro)renin receptor. Int J Mol Med 2009; 24(1): 83-89.
24. Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002; 109(11): 1417-1427.
25. Ichihara A, Hayashi M, Kaneshiro Y, et al. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the handle region for nonproteolytic activation of prorenin. J Clin Invest 2004; 114(8): 1128-1135.
26. Nabi AH, Biswas KB, Nakagawa T, Ichihara A, Inagami T, Suzuki F. Prorenin has high affinity multiple binding sites for (Pro)renin receptor. Biochim Biophys Acta 2009; 1794(12): 1838-1847.
27. Takahashi H, Ichihara A, Kaneshiro Y, et al. Regression of neph-ropathy developed in diabetes by (Pro)renin receptor blockade. J Am Soc Nephrol 2007; 18(7): 2054-2061.
28. Derkx FH, Schalekamp MA: Human prorenin: pathophysiology and clinical implications. Clin Exp Hypertens A 1988; 10(6): 1213-1225.
29. Luetscher JA, Kraemer FB, Wilson DM, Schwartz HC, Bryer-Ash M. Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications. N Engl J Med 1985; 312(22): 1412-1417.
30. Luetscher JA, Kraemer FB, Wilson DM. Prorenin and vascular complications of diabetes. Am J Hypertens 1989; 2(5 Pt 1): 382-386.
31. Deinum J, Ronn B, Mathiesen E, Derkx FH, Hop WC, Schalekamp MA. Increase in serum prorenin precedes onset of microalbuminu-ria in patients with insulin-dependent diabetes mellitus. Diabetologia 1999; 42(8): 1006-1010.
32. Veniant M, Menard J, Bruneval P, Morley S, Gonzales MF, Mullins J. Vascular damage without hypertension in transgenic rats expressing prorenin exclusively in the liver. J Clin Invest 1996; 98(9): 1966-1970.
33. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345(12): 861-869.
34. Kaneshiro Y, Ichihara A, Sakoda M, et al. Slowly progressive, angiotensin II-independent glomerulosclerosis in human (Pro)renin receptor-transgenic rats. J Am Soc Nephrol 2007; 18(6): 1789-1795.
35. Kaneshiro Y, Ichihara A, Takemitsu T, et al. Increased expression of cyclooxygenase-2 in the renal cortex of human prorenin receptor gene-transgenic rats. Kidney Int 2006; 70(4): 641-646.
36. Liebau MC, Lang D, Bohm J, et al. Functional expression of the renin-angiotensin system in human podocytes. Am J Physiol Renal Physiol 2006; 290(3): F710-719.
37. Song RH, Singh AK, Leehey DJ. Decreased glomerular proteinase activity in the streptozotocin diabetic rat. Am J Nephrol 1999; 19(3): 441-446.
38. Leehey DJ, Song RH, Alavi N, Singh AK. Decreased degradative enzymes in mesangial cells cultured in high glucose media. Diabetes 1995; 44(8): 929-935.
39. He M, Zhang L, Shao Y, et al. Angiotensin II type 2 receptor mediated angiotensin II and high glucose induced decrease in renal renin/prorenin receptor expression. Mol Cell Endocrinol 2010; 315(1-2): 188-194.
40. Siragy HM, Huang J. Renal (Pro)renin receptor upregulation in diabetic rats through enhanced angiotensin AT1 receptor and NADPH oxidase activity. Exp Physiol 2008; 93(5): 709-714.
41. Huang J, Siragy HM. Glucose promotes the production of interleu-kine-1{beta} and cyclooxygenase-2 in mesangial cells via enhanced (Pro)Renin receptor expression. Endocrinology 2009; 150(12): 5557-5565.
42. Durvasula RV, Shankland SJ. Mechanical strain increases SPARC levels in podocytes: implications for glomerulosclerosis. Am J Physiol Renal Physiol 2005; 289(3): F577-584.
43. Petermann AT, Hiromura K, Blonski M, et al. Mechanical stress reduces podocyte proliferation in vitro. Kidney Int 2002; 61(1): 40-50.
44. Petermann AT, Pippin J, Durvasula R, et al. Mechanical stretch induces podocyte hypertrophy in vitro. Kidney Int 2005; 67(1): 157-166.
45. Durvasula RV, Petermann AT, Hiromura K, et al. Activation of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int 2004; 65(1): 30-39.
46. Sakoda M, Ichihara A, Mito-Kurauchi A, et al. Aliskiren inhibits intracellular angiotensin II levels without affecting (Pro)renin receptor signals in human podocytes. Am J Hypertens 2010; 23(5): 575-580.
47. Huang Y, Wongamorntham S, Kasting J, et al. Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int 2006; 69(1):105-113.
48. Cousin C, Bracquart D, Contrepas A, Corvol P, Muller L, Nguyen G. Soluble form of the (Pro)renin receptor generated by intracellu-lar cleavage by furin is secreted in plasma. Hypertension 2009; 53(6): 1077-1082.